The Bull Rankings scorecard — our quality-growth score is 79.4 / 100, built from three pillars scored 0–100: Quality 90, Growth 82, Value 68 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 5% a year next year, fading to 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
ResMed’s current price is a fair‑priced bet on quality. The Bull Rankings model gives it a 79.4/100 quality‑growth score, with Quality 90 as the strongest pillar and Value 68 as the softest. A 90‑level quality rating means the company’s earnings are consistently high‑margin, its cash‑flow generation is robust, and its capital structure is lean (debt‑to‑equity 0.13). The 68 Value score tells us the stock sits on the cheaper side of its sector peers, yet it is not a bargain; it is simply priced against a modest growth outlook. The model’s signal that RMD is raising its dividend and enjoys durable high returns further cements the case that the market is already pricing in a solid, if not spectacular, future.
Three figures anchor this thesis:
- Profit margin 26.9% – a high, sustainable margin that protects earnings from price pressure.
- Free‑cash‑flow $1.6 b – enough to fund growth, pay dividends, and return capital to shareholders.
- P/E 21.4 – below the Healthcare median (~40th percentile), indicating the stock is not overvalued relative to peers.
Together, they paint a picture of a company that can keep compounding its earnings while delivering shareholder value at a reasonable multiple.
What the business actually is
ResMed operates in two core segments: Sleep and Breathing Health and Residential Care Software. In the first segment it sells diagnostic devices such as ApneaLink Air and NightOwl, which capture oximetry, respiratory effort, pulse, nasal flow, and snoring data. These devices are used in sleep clinics, hospitals, and at home, providing a scalable, cloud‑connected platform for sleep apnea diagnosis and titration. The second segment, Residential Care Software, offers solutions like EasyCare Tx and the AirView cloud platform, enabling remote monitoring and management of patients with chronic respiratory conditions. The combination of hardware and software creates a recurring revenue stream that fuels the company’s growth engine.
Why it can (or can't) keep compounding
The durability of ResMed’s moat lies in its high‑margin, cloud‑connected ecosystem. With a 26.9% profit margin and a 23.1% ROE, the company turns revenue into cash far more efficiently than most peers. The low debt‑to‑equity ratio of 0.13 means capital is cheap, allowing the firm to invest in product innovation without diluting shareholders. The AirView platform locks customers into a digital health ecosystem that competitors find hard to replicate quickly; data ownership, regulatory approvals, and established clinical workflows create a high switching cost. The Bull Rankings model’s signal that RMD is raising its dividend is a tangible sign that the company is confident in its cash‑flow generation and willing to share excess value with investors.
The valuation question
The market is already pricing in a reverse‑DCF implied growth of about 5% per year in year 1, tapering to 4% by year 10. This starting rate is lower than the trailing revenue growth of 9.9%. In plain terms, the stock assumes that the business will slow down after the current surge. The P/E of 21.4, below the sector median, reflects this modest optimism. The model’s Value score of 68 confirms that the price is on the cheaper side of peers, yet it is not a bargain because the implied growth is conservative. Therefore, the valuation is neither overly optimistic nor pessimistic; it simply discounts the recent revenue acceleration.
The bear case
The most compelling skeptic argument centers on growth sustainability. The reverse‑DCF implied growth of 5% versus the recent 9.9% revenue growth suggests the market is already discounting future expansion. If the company fails to maintain its current revenue momentum—say, if the revenue growth drops below 8%—the implied growth gap would widen, eroding the valuation cushion. A concrete signal that would confirm this scenario is a decline in the free‑cash‑flow margin below 5%, indicating that the high margins are under pressure.
What would change our mind
- Revenue growth falling below 8% would weaken the growth pillar and push the model’s implied growth further below the business reality.
- Profit margin slipping below 25% would erode the Quality pillar, signaling cost pressures or pricing power erosion.
- Dividend increase exceeding 10% would be a positive surprise, but if accompanied by a decrease in free‑cash‑flow or a rise in debt‑to‑equity above 0.20, the Value pillar would deteriorate, turning the stock into a less attractive play.
If any of these thresholds are breached, the thesis would shift from a solid quality play to a more cautious stance.